InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,702.55
(
-0.19%
)
US TECH 100
19,287.60
(
-0.24%
)
Dow Jones
42,063.36
(
0.09%
)
Brent Oil
74.46
(
0.77%
)
Bitcoin
63,836.30
(
0.34%
)
Post# of 253175
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 840
Posts 120476
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Bickema post# 210919

Thursday, 04/27/2017 5:01:59 PM

Thursday, April 27, 2017 5:01:59 PM

Post# of 253175
EXAS—(+27%)—raised 2017 guidance big-league:

http://investor.exactsciences.com/investor-relations/press-releases/press-release-details/2017/Cologuard-growth-accelerates-to-484-million-in-revenue-during-first-quarter-volume-grows-150-percent-year-over-year-to-100000-completed-tests/default.aspx


• Revenue guidance raised to $195-205 million for 2017, from $170-180 million [the prior 2017 guidance];

• Guidance for completed Cologuard tests increased to at least 470,000 tests, from at least 415,000 [the prior 2017 guidance].

Although EXAS is not yet profitable, the business is slowly but surely growing into the stock’s (somewhat lofty) valuation. I think Cologuard is a fine product.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up